Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: zagnut1 who wrote (873)	2/17/2025 5:37:07 PM
From: TinfoilHat	5 Recommendations Recommended By erippetoe jargonweary luckydog88 Olecranon recarte Read Replies (1) \| Respond to of 1230

On the scientific front, a micro-cap NK player just got Fast Track Designation for moderate Alzheimer's disease. Two key takeaways: Anktiva could play a role in dementia, which would make the total addressable market ludicrous, and IBRX could acquire this micro-cap player to accelerate into Alzheimer's. I prefer the former. Am not invested in NKGen, for the record, but can see IBRX go bananas if/when PSS announces a study in Alzheimer's focusing on neuro-inflammation as RFK is known to be anti-amyloid. Look out above if IBRX gains a toe-hold in the behemoth of all diseases, and sky is the limit if Anktiva shows a signal. Any science nerds out there know the difference between Anktiva and Troculeucel? My basic understanding is Anktiva is an IL-15 complex, and Troculeucel is just a basic autologous NK. Seems IBRX should have a competitive tool already inhouse, no need to acquire Troculeucel. FDA Grants Fast Track Designation to Troculeucel for Moderate Alzheimer Disease